BCT vs. HBP, MBX, APS, RVX, TH, ATE, AEZS, ONC, SVA, and MDNA
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Helix BioPharma (HBP), Microbix Biosystems (MBX), Aptose Biosciences (APS), Resverlogix (RVX), Theratechnologies (TH), Antibe Therapeutics (ATE), Aeterna Zentaris (AEZS), Oncolytics Biotech (ONC), Sernova (SVA), and Medicenna Therapeutics (MDNA). These companies are all part of the "biotechnology" industry.
Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.
13.9% of BriaCell Therapeutics shares are owned by institutional investors. 20.5% of Helix BioPharma shares are owned by company insiders. Comparatively, 12.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Helix BioPharma has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.
Helix BioPharma received 65 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
Summary
BriaCell Therapeutics beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
